首页> 外文期刊>BMC Cancer >The clinical significance of FAM19A4 methylation in high-risk HPV-positive cervical samples for the detection of cervical (pre)cancer in Chinese women
【24h】

The clinical significance of FAM19A4 methylation in high-risk HPV-positive cervical samples for the detection of cervical (pre)cancer in Chinese women

机译:高危HPV阳性子宫颈样品中FAM19A4甲基化对中国女性子宫颈癌的检测的临床意义

获取原文
       

摘要

To explore the diagnostic value of FAM19A4 methylation in high-risk human papilloma virus (hrHPV)-positive cervical samples from Chinese women for estimating cervical cancer or its precancerous lesions. Cervical samples from 215 women infected with high-risk HPV were collected by smear testing. We purposely chose 61 patients with cervical cancer, 57 with high-grade squamous intraepithelial lesions (HSIL), 31 with low-grade squamous intraepithelial lesions (LSIL), and 66 without cervical intraepithelial neoplasia (CIN) after histological confirmation. Taqman probe-based quantitative PCR (qPCR) was utilized to detect the methylation status of FAM19A4 in the cervical samples and further evaluate the use of this gene in the diagnosis of cervical cancer. (1) An increasing level of FAM19A4 methylation was detected with increasing progression of cervical lesions, with methylation rates of 10.61%(7/66), 35.48%(11/31), 56.14%(32/57) and 93.44%(57/61) in no CIN, LSIL, HSIL and cervical carcinoma samples respectively. (2) In all hrHPV-positive samples, the levels of FAM19A4 methylation in HPV16/18 groups were higher than that in 12 other hrHPV groups (P 0.05). (3)There were no significant differences of FAM19A4 methylation in different clinicopathological parameters of cervical cancer. (4) Though the sensitivity of FAM19A4 methylation test was inferior to that of cytology and FAM19A4 combining with HPV16/18 genotyping, but showed the best specificity with 81.44% both for detection HSIL alone and?≥?HSIL, with favorable youden index (YI) and area under curve (AUC). FAM19A4 is a specific biomarker of cancerous lesions of the cervix. FAM19A4 methylation analysis may serve as an auxiliary screening method for diagnosis of cervical (pre)cancer. However, in consideration of the limitations of this retrospective study, prospective population-based studies are necessary for further confirmation of the diagnostic value of FAM19A4 methylation for detection of cervical (pre)cancer in Chinese women.
机译:探讨FAM19A4甲基化在高危人乳头瘤病毒(hrHPV)阳性中国女性宫颈样本中对宫颈癌或其癌前病变的评估价值。通过涂片测试收集了215名高危HPV感染妇女的宫颈样本。经组织学确认后,我们特意选择了61例宫颈癌患者,57例高度鳞状上皮内病变(HSIL),31例低度鳞状上皮内病变(LSIL)和66例无宫颈上皮内瘤变(CIN)的患者。基于Taqman探针的定量PCR(qPCR)用于检测宫颈样品中FAM19A4的甲基化状态,并进一步评估该基因在宫颈癌诊断中的用途。 (1)随着宫颈病变程度的增加,FAM19A4甲基化水平升高,甲基化率分别为10.61%(7/66),35.48%(11/31),56.14%(32/57)和93.44%(57) / 61)分别没有CIN,LSIL,HSIL和宫颈癌样本。 (2)在所有hrHPV阳性样本中,HPV16 / 18组的FAM19A4甲基化水平均高于其他12个hrHPV组(P 0.05)。 (3)在宫颈癌的不同临床病理参数中,FAM19A4甲基化程度无明显差异。 (4)尽管FAM19A4甲基化测试的敏感性不如细胞学和FAM19A4结合HPV16 / 18基因分型的敏感性,但对单独检测HSIL和≥?HSIL的特异性最高,为81.44%,尤登指数(YI)良好)和曲线下面积(AUC)。 FAM19A4是宫颈癌性病变的特定生物标记。 FAM19A4甲基化分析可作为诊断宫颈癌的辅助筛选方法。但是,考虑到这项回顾性研究的局限性,有必要进行基于人群的前瞻性研究,以进一步确认FAM19A4甲基化对中国女性宫颈癌(前)癌的诊断价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号